Keymed Biosciences, Inc. 2162
HKEX · Hong Kong SAR China · Health Technology
HKD 81.55+1.95 (+2.45%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in d
Belenos and Keymed will now look to initiate Phase III studies for their co-developed drug in Dupixent-dominated CRSwNP.
SARASOTA, Fla., August 11, 2026--Belenos Biosciences Announces Positive CRSwNP Results
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.